RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsSo as Morningstar reported on August 10, 2022 - "We see strong underlying reasons to expect a big increase in deal activity. Whether or not prospective big deals like Merck's rumored acquisition of Seagen close, we have already seen certain Big Pharma players returning to M&A in the second quarter of 2022," Subin Baral, EY's global life sciences deals leader, said in an email. "We anticipate that this trend will continue."
These deals hint at an action-packed second half.
"2022 will be a year of bolt-on transactions in the $5 [billion] to $15 billion range," the PwC authors wrote. "However, don't rule out the potential for larger deals -- consolidation is good for the health ecosystem and drives broader efficiency."
https://www.morningstar.com/news/marketwatch/20220810210/get-ready-for-more-merger-mania-in-the-pharma-sector-for-the-rest-of-the-year